论文部分内容阅读
目的:通过DNA-PKcs表达抑制的细胞模型,研究DNA-PKcs与癌基因c-myc表达调控的关系。方法:利用siRNA技术或抑制剂建立DNA-PKcs表达抑制细胞模型,Western印迹检测DNA-PKcs和c-Myc蛋白表达变化,Northern印迹检测癌基因c-myc的mRNA表达,SEAP检测系统检测c-myc转录活性变化。结果:稳定表达DNA-PKcssiRNA的细胞DNA-PKcs蛋白和c-Myc蛋白表达明显降低,同时c-myc转录活性也被抑制,但c-myc在mRNA水平无明显变化。渥曼青霉素(wortmannin,0.2μmol/L)同样也可抑制c-Myc蛋白表达和转录活性,而对c-myc的mRNA表达无影响。结论:DNA-PKcs参与c-myc基因的表达调控,DNA-PKcs是一个潜在的肿瘤治疗靶分子。
OBJECTIVE: To study the relationship between the expression of DNA-PKcs and the expression of oncogene c-myc through the cell model of DNA-PKcs expression inhibition. Methods: The cell model of DNA-PKcs expression was established by siRNA or inhibitor. The changes of DNA-PKcs and c-Myc protein were detected by Western blotting. The expression of c-myc mRNA was detected by Northern blotting. Changes in transcriptional activity. Results: The expression of DNA-PKcs protein and c-Myc protein in cells stably expressing DNA-PKcssiRNA was significantly decreased, while the transcription activity of c-myc was also inhibited. However, c-myc mRNA level did not change significantly. Wortmannin (0.2μmol / L) also inhibited c-Myc protein expression and transcription activity, but had no effect on c-myc mRNA expression. Conclusion: DNA-PKcs is involved in the regulation of c-myc gene expression. DNA-PKcs is a potential target for tumor therapy.